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In rats challenged with viridans streptococci poorly susceptible to antibiotic killing, sin-
gle doses of antibiotics only prevent endocarditis induced by bacterial inoculum sizes that
produce disease in 90010 of control animals (109 0) : additional doses are required to protect
against inocula exceeding the 109 0 • Weinvestigated whether single-dose rifampin would
extend the efficacy of single-dose prophylaxis to inocula exceeding the 109 0 • Weused two
strains of viridans streptococci highly susceptible to killing by rifampin and two resistant
strains. All rats were injected with to-I,OOO times the 109 0 of the four strains. Single-dose
rifampin successfully prevented endocarditis due to all four strains. A few prophylaxis
failures were observed after challenge with the two poorly susceptible strains, but in vivo
emergence of resistant variants did not account for these failures. Thus, rifampin was
the first antibiotic given as a single dose that successfully prevented experimental strep-
tococcus endocarditis after challenge with high bacterial inocula.
Experimental streptococcus endocarditis can be suc-
cessfully prevented by single doses of cell wall-ac-
tive antibiotics like amoxicillin and vancomycin.
When these antibiotics do not rapidly kill the bacte-
ria used for challenge, however, the efficacy of single-
dose prophylaxis is limited to the animals challenged
with the lowest bacterial inoculum that infects 90070
of controls (ID 9o) [1-3]. Isolates of viridans strep-
tococci poorly susceptible to the bactericidal action
of cell wall-active antibiotics are increasingly re-
ported from patients with endocarditis [4] and
among other clinical isolates of a-hemolytic strep-
tococci [5]. Against these bacteria, even a single dose
of a synergistic combination of amoxicillin plus gen-
tamicin failed to protect animals challenged with in-
ocula exceeding the ID 9o[6], and successful preven-
tion of endocarditis could only be achieved by
administering multiple doses of antibiotics that pro-
vide sustained blood levels after bacterial challenge
(R. M., P. Francioli, M. P. G., unpublished observa-
tions).
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In the present experiments we tested the ability
of rifampin to prevent experimental streptococcal en-
docarditis. We chose rifampin for two reasons. First,
rifampin produces sustained blood levels in both rats
and humans after single-dose administration [7,8].
This pharmacological property permitted us to in-
vestigate whether single-dose rifampin, unlike single-
dose amoxicillin or vancomycin, would prevent en-
docarditis induced by bacterial inocula higher than
the ID 9 0 of the test organisms. Second, rifampin has
excellent in vitro activity against viridans streptococci
[9]. We used single-dose rifampin prophylaxis against
four different Streptococcusstrains that were injected
into rats at inocula 10-1,000 times the ID 9 0 of the
strains.
Materials and Methods
Microorganisms. Four strains of viridans strep-
tococci isolated from patients with endocarditis were
used. Streptococcus intermedius and Streptococcus
sanguis (originally provided by Dr. D. Durack, Duke
University Medical School, Durham, NC) have pre-
viously been used in experiments in rabbits [10, 11]
and in rats [1-3, 6, 12]. In addition, two strains of
Streptococcus mitis, S. mitis 1000 [6] and S. mitis
518, were selected. These strains were selected be-
cause, from 23 strains of a-hemolytic streptococci
isolated from patients with bacterial endocarditis in
our hospital, S. mitis 1000 and S. mitis 518 were the
most susceptible to the bactericidal action of ri-
fampin.
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MICs, MBCs, and rates ofkilling. The MICs of
rifampin (Ciba-Geigy, Basel, Switzerland) for the
four test organisms were determined by a standard
broth-dilution procedure [13] using an inoculum of
105 organisms from an overnight culture. The MBCs
were determined by subculturing onto blood agar
plates 10-fold and lOO-foldbroth dilutions of a 0.1-
ml sample from each dilution showing no turbidity
after 18 hr of incubation. This dilution procedure
was used to avoid the carryover of antibiotic, a
phenomenon that can give falsely low MBCs. After
48 hr of incubation the number of colonies on each
plate was counted, and the MBC was determined as
the lowest dilution of antibiotic that showed 99.9070
killing.
Using a concentration of 10 ug of rifampin/rnl,
we determined the rates of killing of the four test
organisms in tryptic-soy broth (Difco, Detroit) by
using a 105 inoculum from an overnight culture. A
concentration of 10 ug of rifampin/ml was chosen
because it was similar to peak serum levels in rats
after receiving 20 mg of rifampin/kg sc and in hu-
mans after receiving 600 mg orally [8, 14]. At vari-
ous times after inoculating the bacteria into the
antibiotic-containing broth, 10-1 , 10-3 , and 10-5 di-
lutions of a OJ-ml sample were subcultured onto
blood agar plates and were incubated for 48 hr be-
fore colony counts were done.
Serum levels and activities. Serum levels of ri-
fampin were determined by a standard agar-diffusion
technique using Sarcina lutea (ATCC 9341) as the
test organism and antibiotic medium no. 1 (Difco)
[15]. Normal rat serum was used as the diluent. The
samples were taken 2, 4, 8, 12, and 24 hr after an
sc injection of 20 mg of rifampin/kg (water-soluble
rifampin sodium salt; Ciba-Geigy) into groups of five
rats for each time point.
Serum inhibitory activity (SIA) and serum bacte-
ricidal activity (SBA) for S. intermedius, S. sanguis,
S. mitis 1000, and S. mitis 518 were determined 4,
8, 12, and 24 hr after an sc injection of 20 mg of
rifampin/kg by standard methods [16], using an in-
oculum of 105 cfu/ml for each strain. Subcultures
were performed on blood agar plates by plating 10-
fold and loo-fold dilutions of a OJ-ml sample of each
dilution. The SIA was the highest serum dilution in-
hibiting visible bacterial growth, and the SBA was
the highest serum dilution providing 99.9070 killing
of the original inoculum after 18 hr of incubation.
Rifampin-resistant variants in vitro. Because two
strains of viridans streptococci, S. sanguis and S. in-
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termedius, were not susceptible to the bactericidal
action of rifampin, we investigated whether the lack
of bacterial killing was due to the presence of
rifampin-resistant subpopulations among these two
strains. Experiments were performed as previously
described to determine rates of killing. Briefly, using
a 106 bacterial inoculum from an overnight culture,
we determined the rates of killing of S. intermedius
and S. sanguis by using a concentration of 10 Ilg of
rifampin/ml. Before and after 12 and 24 hr of ex-
posure to rifampin, 0.1 ml of undiluted 10-2 , 10-4 ,
and 10-6 dilutions of control and rifampin-exposed
vials were subcultured onto blood agar plates and
onto plates containing 1, 10, and 100 ug of rifam-
pin/ml. The plates were incubated for 48 hr before
colonies were counted. We used an additional 108
cfu inoculum to search for rifampin-resistant vari-
ants in the initial inoculum (i.e., without prior ex-
posure to the drug).
Rifampin-resistant variants in vivo. After the
rats were killed, OJ-ml samples of undiluted homog-
enates of vegetation suspended in 0.85070 NaCI from
rats given rifampin prophylaxis were directly plated
onto blood agar plates containing 1, 10, and 100 Ilg
of rifampin/ml. The plates were incubated for 48 hr
before the colonies were counted.
Adhesion of S. intermedius and S. sanguis to
platelet-fibrin matrices. Experiments were per-
formed by using an in vitro assay system that simu-
lated nonbacterial thrombotic vegetations, as de-
scribed previously [17]. The aim of these experiments
was to investigate in vitro whether inhibition of bac-
terial adherence was a likely mechanism for success-
ful rifampin prophylaxis against the two Strep-
tococcus strains poorly susceptible to killing. In
brief, cultures of S. intermedius and S. sanguis were
grown overnight in tryptic-soy broth and suspended
at a final concentration of 104 cfu/ml in PBS sup-
plemented with 10 ug of rifampin/ml. Control bac-
teria were suspended in PBS alone. The suspensions
were immediately poured into petri dishes contain-
ing the fibrin-platelet matrices and were incubated
for 5 min at 37 C in a shaking incubator. The super-
natant was then removed, and the matrices were
washed two times for 5 min each with rifampin or
PBS alone. This total time of exposure to rifampin
(15 min) was chosen to simulate the mean duration
of bacteremia after intravenous challenge, during
which time inhibition of adherence has to occur if
it is to prevent endocarditis [2]. The petri dishes were
then washed 10times for 1 min each with PBS alone,
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a procedure used to rapidly and completely elimi-
nate rifampin from the matrices.
Endocarditis. Sterile vegetations were produced
in female Wistar rats (180-200 g) by a previously de-
scribed method [1]. In brief, a polyethylene catheter
was inserted via the right carotid artery through the
aortic valve into the left ventricle and secured with
a silk ligature. Twenty-four hours after this proce-
dure, rats were injected iv with 0.5 ml of 0.85070 NaCI
containing 108 cfu of S. mitis 518, S. intermedius,
or S. sanguis test organisms or containing 107 cfu
of S. mitis 1000 from an overnight culture.
The 109 0 was determined as previously described
[3]. In brief, the 109 0 of S. intermedius and S. mitis
1000 was 105 cfu/ml; of S. sanguis, 106 cfu/ml; and
of S. mitis 518, 107 cfu/ml. Thus, the inocula used
in the prophylaxis experiments were 1,000 times the
109 0 of S. intermedius, 100 times the 109 0 of S. san-
guis and S. mitis 1000, and 10times the 109 0 of S. mi-
tis 518.
For S. mitis 1000, S. intermedius, and S. sanguis,
we have previously established [6] that single-dose
amoxicillin prophylaxis failed against inocula higher
than the 109 0 , For S. mitis 518, we established a simi-
lar phenomenon by using an inoculum size of 108
cfu/ml.
Prophylaxis. Four hours before challenge with
the four test organisms, groups of rats were injected
sc with either 20 mg of rifampin/kg or 0.85070 NaCI
alone (controls). The 4-hr interval between rifampin
injection and bacterial challenge was chosen so that
bacteria were injected at the time of peak rifampin
levels.
Evaluation ofinfection. Rats given 0.85070 NaCI
(controls) were killed 72 hr after bacterial challenge.
Rats given rifampin prophylaxis were killed seven
days after bacterial challenge, a period that permit-
ted the full development of endocarditis if rifampin
prophylaxis failed.
After the rats were killed, aortic vegetations were
excised, weighed, homogenized in 1 ml of 0.85070
NaCI, serially diluted, and plated. Colony counts
were determined after 48 hr of incubation at 37 C.
This method permitted us to detect 102 cfu of bacte-
ria/g of vegetation.
Statistics. The x/ test with Yates' correction and
the unpaired Student's t test were used for statistical
comparisons.
Results
MICs, MBCs, and ratesofkilling. The MICs and
MBCs, respectively, of rifampin for the four test or-
ganisms were 0.016and 0.032 ug/ml for S. mitis 1000,
0.008 and 0.064 ug/rnl for S. mitis 518, 0.032 and
16 ug/ml for S. intermedius, and 0.032 and 32 ug/rnl
for S. sanguis. Thus, the first two strains exhibited
MBC values close to their MICs, in contrast to the
latter two strains, which showed higher MBC values.
The rates of in vitro killing of the four test organ-
isms by 10 ug of rifampin/ml (simulating peak se-
rum levels 4 hr after prophylaxis) are shown in fig-
ure 1. Bacterial counts of both S. intermedius and
S. sanguis were not significantly reduced by peak
concentrations of rifampin over 24 hr of incubation,
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Figure 1. Rates of in vitro killing of
four strains of viridans streptococci by
10J.Lg of rifampin/ml (a concentration
similar to peak serum levels in rats 4
hr after receiving 20 mg of rifampin/kg
sc). I, S. sanguis; 2, S. intermedius; 3,
S. mitis 1000; and 4, S. mitis 518.
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whereas both strains of S. mitis were killed within
6 and 12 hr.
Rifampin-resistant variants of S. sanguis and
S. intermedius. When S. sanguis was tested at an
inoculum of lOS cfu, the frequency of resistant vari-
ants without prior exposure to rifampin was 10-7
(MIC, ~256 ug/ml), At the 106 cfu inoculum, no
rifarnpin-resistant variants could be detected with-
out prior exposure to rifampin. In contrast, inocula
exposed to rifampin for 12 hr showed a 10-3 fre-
quency of resistant variants (MIC, ~512 ug/ml). Af-
ter 24 hr of exposure, all the colonies tested were
highly resistant to rifarnpin.
When S. intermedius was tested at inocula of 106
and lOS cfu, no rifampin-resistant variants were de-
tected without prior exposure to rifampin. When a
106 cfu inoculum was exposed to rifarnpin, however,
the frequency of resistant variants was 10-2 (MIC,
~1,024- ug/ml) after 12 hr of exposure, and all the
colonies tested were highly resistant to rifampin
(MIC, 512-1,024 ug/rnl) after 24 hr of exposure.
Thus, the bacteriostatic effect of rifampin on S. in-
termedius and S. sanguis, observed when perform-
ing killing curves, was due to the selection of vari-
ants highly resistant to rifampin.
MICs and MBCs of23 strains of viridans strep-
tococci. The MICs of rifampin for all 23 strains
of a-hemolytic streptococci isolated from patients
with endocarditis were <0.064 ug/ml, Nineteen
(83010) of 23 strains had MBC values that exceeded
their MIC values >32 times.
Serum levels and activities. Two hours after rats
were injected sc with 20 mg of rifampin/kg, the mean
± SD serum level was 9.1 ± 1.4 ug/rnl; after 4 hr
this value was 14.2 ± 1.26 ug/ml. Thus, peak serum
levels were observed 4 hr after injection. The mean
± SD values 8, 12, and 24 hr after injection were
10.9 ± 1.22 ug/ml, 7.6 ± 0.8 ug/rnl, and 0.4 ±
0.1 ug/ml, respectively.
After 36 rats were injected sc with 20 mg of ri-
fampin/kg, no SBA against S. intermedius or S. san-
guis could be detected at any time; however, SIAs
of >1:16 could be detected until 12 hr after injec-
tion. Against S. mitis 518, the mean SBAs were 1:16,
1:8, and 1:4 at 4, 8, and 12hr, respectively, after in-
jecting five rats at each time point. Against S. mitis
1000, the SBAs were 1:8, 1:4, and 1:2 at 4, 8, and
12hr after injection, respectively. Thus, only serum
inhibitory titers were detected against the tolerant
strains, whereas serum bactericidal titers were de-
tected for up to 12 hr against the susceptible strains.
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Prophylaxis with rifampin. Figure 2 shows the
results of single-dose rifampin prophylaxis against
the four Streptococcus strains. Rifampin completely
prevented endocarditis induced by the two strains
that were highly susceptible to killing by rifampin
(S. mitis 1000andS. mitis 518); the vegetations from
all 38 animals weresterile seven days after bacterial
challenge (P< .001 when compared with controls).
Single-dose rifampinalso significantly protected
(P < .001 for both strainswhen compared with con-
trols) against endocarditis induced by the two strains
not killed by rifampin (S. intermedius and S. san-
guis); however, prophylaxis failures, were observed
in seven of 25 rats challenged with S. intermedius
and in four of 23 rats challenged with S. sanguis.
The mean bacterial densities of the vegetations from
the prophylaxis failures were significantly less than
those in controls (P< .003), despite the fact that all
animals given rifampin were killed seven days after
administration of the antibiotic.
Adhesion of S. intermedius and S. sanguis to
platelet-fibrin matrices. Because S. intermedius
and S. sanguis were not killed by rifampin in vitro,
we investigated whether successful prophylaxis with
rifampin might have been mediated through dimin-
ished adherence of the organisms to cardiac valves.
We therefore tested the influence of rifampin on the
in vitro adherence of these two microorganisms to
platelet-fibrin matrices. When incubated in vitro with
10 J,1g of rifampin/ml for 15 min, the adherence ra-
tio (mean ± SD of 60 determinations) of S. inter-
medius was 0.091 ± 0.068 for controls (PBS alone)
and 0.14 ± 0.088 for rifampin-incubated organisms
(P> .05, Student's t test). For S. sanguis, the mean
adherence ratio (60 determinations) was 0.072 ±
0.034 for controls and 0.063 ± 0.035 for rifampin-
incubated organisms (?> .05, Student's t test). Thus,
rifampin did not significantly influence the in vitro
adhesion of S. intermedius or S. sanguis to platelet-
fibrin matrices.
Rifampin-resistant variants in vivo. When sam-
ples of undiluted homogenates of the vegetations
from the prophylaxis failures were plated onto
rifampin-containing blood agar plates, none of the
sevenS. intermedius failures and only one of the four
S. sanguis failures showed decreased susceptibility
to rifampin. In the latter case, a few S. sanguis colo-
nies grew on plates containing 1 J,1g of rifampin/ml,
but none grew on plates containing 10or 100ug/ml.
Thus, only one of 11 vegetations that was not pro-
tected from infection by single-dose rifampin pro-
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Figure 2. Incidence ofendocarditis (number of rats with endocarditis/total number of rats challenged with each strain)
in control (C) rats and in rats given single-dose rifampin prophylaxis (R) 4 hr before challenge with four strains of
viridans streptococci. The inoculum size of each strain used for challenge was 10-1,000 times the 1090 , The MICs and
MBCs of rifampin are indicated for each strain. The mean (± SO) bacterial densities (MBD) recovered from vegeta-
tions (expressed in cfu/g of vegetation) are indicated for each group. To compare the incidence of endocarditis in con-
trol rats to that in rats given rifampin prophylaxis, we calculated P values by x,'l' with Yates' correction; * = P < .001.
Tocompare MBOs in controls to those in rats given rifampin prophylaxis, we calculated P values by unpaired Student's
t test; t = P < .003.
phylaxis harbored streptococci with decreased in
vitro susceptibility to rifampin.
Discussion
Experiments in both rabbits and rats have shown that
when animals are challenged with organisms poorly
susceptible to antibiotic killing, successful prophy-
laxis conferred by single doses ofantibiotics is limited
to the IDgo and fails when the animals are challenged .
with inocula higher than the IDgo [3, 6]. In the latter
condition, endocarditis can be prevented only by
prolonged levels of antibiotics, such as are achieva-
ble after multiple doses [18; R. M., P. Francioli,
M. r.o, unpublished observations]. Because most
strains of viridans streptococci appear to be poorly
susceptible to the bactericidal action of cell wall-ac-
tive antibiotics [4, 5], drugs providing high and
prolonged serum antibiotic activity after a single
dose should be investigated for preventing experi-
mental bacterial endocarditis after challenge with
heavy loads of bacteria.
The present results show that single-dose rifam-
pin, which produces SIAs for >12 hr for all four
strains tested, provided successful prophylaxis
against very high bacterial inocula, irrespective of
whether the organisms used for challenge were killed
rapidly by the drug.
Against challenge with both S. mitis 1000 and
S. mitis 518 (the two strains highly susceptible to kill-
ing by rifampin, as indicated by the high serum bac-
tericidal levels in vivo and by time-kill curves in
vitro), it is likely that protection was provided
through bacterial killing. Previous experiments in
rats [3] have shown that when bacteria used for chal-
lenge are killed rapidly enough in vitro that the in-
travenous bacterial inoculum is likely to be killed
upon exposure to serum bactericidal levels in vivo,
successful prophylaxis is independent of the inocu-
lum size.
Against S. sanguis and S. intermedius, rapid bac-
terial killing could not account for successful pro-
phylaxis because neither the serum bactericidal ac-
tivity nor the in vitro exposure for 24 hr of both
strains to peak concentrations of rifampin (10ug/ml)
indicated a significant reduction in bacterial num-
bers. In fact, it was established in vitro that this lack
of bacterial killing was due to the selection of rifam-
pin-resistant variants, a phenomenon observed in
only one of 23 rats infected with 108 cfu of S. san-
guis and given rifampin prophylaxis and in none of
25 rats infected with 108 cfu of S. intermedius and
given rifampin prophylaxis.
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In the absence of bacterial killing, one mechanism
of successful endocarditis prophylaxis has been
postulated to be antibiotic-mediated decreased ad-
herence of organisms to damaged valvular endothe-
lium [2, 17, 19]. By using an in vitro assay system
simulating damaged valvular endothelium, ScheId
et al. [17], as well as others [19],have shown that var-
ious cell wall-active antibiotics prevented the adher-
ence of S. sanguis to platelet-fibrin matrices. Rifam-
pin did not, however, influence the in vitro adhesion
ratio of S. sanguis in those experiments, nor did it
in the present experiments, when concentrations of
rifampin >156 times the MICs of the two strains were
used. Thus, the reduction of bacterial adherence by
rifampin prophylaxis was not a likely mechanism
operating to prevent endocarditis due to S. inter-
medius and S. sanguis in the present experiments.
Recent observations [18] have provided evidence
that in the absence of rapid bacterial killing, the in-
hibition of growth of bacteria attached to the vege-
tations after intravenous challenge may be an im-
portant mechanism of protection after antibiotic
prophylaxis, by permitting release of the bacteria that
had colonized the vegetations. The longer the dura-
tion of growth inhibition, the greater the likelihood
of successful prophylaxis after challenge with inoc-
ula exceeding the ID go [18]. In the present experi-
ments, single-dose rifampin provided serum levels
above the MIC for both S. intermedius and S. san-
guis for at least 12 hr. Moreover, it is likely that ri-
fampin provided growth inhibition for a longer du-
ration than the mere period of circulating rifampin
levels: Bacterial numbers in vegetations from pro-
phylaxis failures seven days after administration of
rifampin were significantly lower than in controls,
a result suggesting a prolonged in vivo suppression
of bacterial growth, A similar phenomenon has been
observed after amoxicillin prophylaxis of strep-
tococcus endocarditis [3] and after rifampin prophy-
laxis of a foreign-body infection due to Staphylo-
coccus aureus [20]. Moreover, a prolonged in vitro
postantibiotic effect has been demonstrated for
rifampin-exposed S. aureus [21].
The rapid development of resistant variants after
administration of rifampin is a major concern. The
lack of in vitro bactericidal activity of rifampin
against S. sanguis and S. intermedius was due to the
emergence of rifampin-resistant subpopulations af-
ter a long exposure to high concentrations of rifam-
pin. In only one instance in vivo, however, could we
detect moderately resistant S. sanguis after rifam-
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pin prophylaxis, a phenomenon that is not signifi-
cant when one considers the total of 48 rats that re-
ceived rifampin before challenge with high bacterial
inocula of S. sanguis and S. intermedius. The ina-
bility of the in vitro observation to predict the in vivo
outcome of prophylaxis might be explained by the
fact that in vivo, both rifampin levels and duration
of antibiotic exposure were less pronounced than in
the in vitro experiments. It might be hypothesized
that, in vivo, rifampin inhibited the growth of (or
slowly killed) the susceptible subpopulation (i.e., the
population with low MICs) of S. intermedius and
S. sanguis and thus accounted for successful prophy-
laxis without selection of resistant variants.
In studies by others [14], the emergence of resis-
tant strains was not observed in vivo when single-
dose rifampin was used for prophylaxis of experi-
mental Staphylococcus epidermidis endocarditis, nor
was it observed after short-term treatment of ex-
perimental staphylococcus osteomyelitis (0. Zak,
personal communication). In contrast, the emer-
gence of rifampin resistance has been detected in ex-
perimental models when high numbers of bacteria
were exposed to rifampin during prolonged periods
of time [22-24]. Although these latter observations
do not support the use of the prolonged adminis-
tration of rifampin as a single therapeutic agent,
short-term, single-dose rifampin prophylaxis might
retain full effectiveness.
In conclusion, single-dose rifampin prophylaxis
of experimental streptococcus endocarditis extended
the protection to bacterial inocula exceeding, by far,
the IDgo of the test strains. The protection was inde-
pendent of whether or not the organisms were sus-
ceptible to bacterial killing by rifampin. Thus, rifam-
pin was the first prophylactic agent that provided
a wide margin of safety against experimental strep-
tococcus endocarditis when given as a single dose.
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